Previous Article | Next Article ![]()
Journal of Virology, July 2004, p. 6946-6954, Vol. 78, No. 13
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.13.6946-6954.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Laboratory of Virology, Wageningen University, 6709 PD Wageningen, The Netherlands
Received 7 November 2003/ Accepted 25 February 2004
|
|
|---|
|
|
|---|
In contrast, BVs of group II NPVs and GVs lack a homolog of GP64. The low-pH-dependent membrane fusion during BV entry by endocytosis is triggered in this case by a so-called F protein (17, 32). F homologs are also found as envelope proteins of the insect errantiviruses while cellular homologs are found in the fruit fly Drosophila melanogaster and in the African malaria mosquito Anopheles gambiae (25, 36). Unlike GP64, the F proteins are structurally similar to fusion proteins from several vertebrate viruses such as orthomyxoviruses and paramyxoviruses. Recently, it has been shown that the GP64 protein in BVs of Autographa californica MNPV (AcMNPV) can be replaced by the F protein of group II NPVs (24), implying that F is functionally analogous to GP64.
Like several mammalian viral envelope fusion proteins, the baculovirus F protein has to be posttranslationally cleaved by a proprotein convertase (furin) to become fusogenic (43). Also, for some errantiviruses it has been shown that the envelope protein is posttranslationally cleaved (31, 38, 39). Cleavage seems to be a general mechanism for viruses to activate their fusion proteins (21). In a number of virus families this cleavage occurs in front of a strongly hydrophobic sequence, the so-called fusion peptide (44, 45). These fusion peptides are believed to translocate upon cleavage to the top of the protein and to insert into the target membrane after exposure to low pH or receptor binding. This translocation facilitates the apposition of viral and cellular membranes upon further conformational changes of the fusion protein (21). Comparison of available F protein sequences reveals a conserved strongly hydrophobic domain with the consensus sequence
GX
B
GXK

GX
DXXDXXX
, where
represents hydrophobic amino acids, B stands for an aspartic acid or an asparagine residue, and X represents any amino acid (Fig. 1). This domain is preceded by a furin-like cleavage site in the F proteins from group II NPVs, GVs, and errantiviruses, whereas this domain is more or less absent in the remnant F protein from group I NPVs and in the cellular homologs (36). This strongly hydrophobic sequence at the N terminus of the membrane-anchored Spodoptera exigua MNPV (SeMNPV) F1 fragment has all the characteristics of a fusion peptide (45). It is well conserved within the virus family (Fig. 1), when modeled in
-helix, it displays one face with a hydrophobic index (H.I.) of about 0.9, according to the normalized consensus scale of Eisenberg (8), and a back face with hydrogen bonding potential, and it contains glycines on one side of the helix (Fig. 2A).
![]() View larger version (104K): [in a new window] |
FIG. 1. Amino acid sequence alignment of the SeMPNV F protein domains near the protease cleavage site with the corresponding domain of the F proteins of group I NPVs (A), dipterans (B), lepidopteran NPVs (C), group II NPVs (D), GVs (E), and errantiviruses (F). Virus and dipteran abbreviations and GenBank accession numbers of the F proteins are shown on the left and right, respectively. The conserved amino acids are boxed. The consensus sequence is shown below the alignment, in which B represents D or N, indicates a hydrophobic amino acid (H.I., 0.12), and X represents any amino acid. A schematic presentation of the SeMNPV F protein, with the consensus sequence shown in gray boxes, is shown at the bottom. N, N terminus; C, C terminus; SP, signal peptide; TM, transmembrane domain; S-S, disulfide bridge.
|
![]() View larger version (26K): [in a new window] |
FIG. 2. (A) Helical wheel presentation of the first 21 N-terminal amino acids of the SeMNPV F1 fragment. The helix is typically amphipathic, with relatively polar amino acids (H.I., 0.48) above the dotted line, with an average H.I. of 0.24, and except for one aspartic acid residue (D), nonpolar amino acids (H.I., >0.62) below the dotted line, with an average H.I. of 0.87. (B) Linear presentation of the first 21 N-terminal amino acids of the SeMNPV F1 fragment preceded by the consensus furin recognition sequence (box). The open arrow indicates the cleavage site. Underlined amino acids are conserved as shown in Fig. 1. Solid arrows indicate the point mutations as well as the substitutions described in this study.
|
|
|
|---|
Donor plasmids containing envelope protein genes.
A silent mutation was introduced into the coding sequence of the SeMNPV F open reading frame to generate an NdeI cloning site. Therefore, nucleotide 525 in the f open reading frame was changed from C to T by PCR-based site-directed mutation, according to the method of Sharrocks and Shaw (37). The 5' mutagenic primer 5'-CGACGCTCACGAACTGCATATGCTCGCCAACACCACAA-3' (underlined and boldface sequences represent an NdeI site and the mutation, respectively) and the 3' primer 5'-GAGAGGCACGGGCCACGAAAGG-3' (primer downstream of the PmeI site) were used in conjunction with plasmid p
FBgusSe8 (24) as a template with Pfu polymerase (Promega). The PCR product (346 bp) was agarose gel purified, and the single strand containing the mutation at the 3' end served as a 3' mutagenic primer in a second PCR with 5' primer 5'-TTATGGATCCATGCTGCGTTTTAAAGTGAT-3' (the underlined sequence represents a BamHI site) with high-fidelity Expand long-template polymerase (Roche). The second PCR product (862 bp) was cloned into pGEM-T (Promega) to generate the intermediate plasmid pGEM-SeFNdeI. Plasmid p
FBgusSeFNdeI was obtained by swapping the BamHI/PmeI fragment of pGEM-SeFNdeI with the same fragment of p
FBgusSe8.
Mutations and deletions in the coding sequence of SeF, encompassing amino acids 151 to 170 were performed as follows. For every mutant, a 5' phosphorylated primer pair (Table 1) was used with pGEM-SeFNdeI as a template and Pfu polymerase (Promega) to amplify the entire vector. Finally, the 5' ends of the PCR products were ligated to its own 3' ends, generating a new restriction endonuclease site at the junction (Table 1). Clones containing the additional restriction site were sequenced to confirm the mutation. The obtained mutations in pGEM-SeFNdeI were introduced into p
FBgusSeFNdeI by swapping the BamHI/NdeI fragments.
|
View this table: [in a new window] |
TABLE 1. Primer pairs generating the desired mutation and a restriction endonuclease sitea
|
FBgusSeFNdeI were transposed into the att Tn7 transposon integrase site of a gp64-null AcMNPV bacmid (provided by G. W. Blissard) (24) according to the Bac-to-Bac manual (Invitrogen). Transpositions of inserts from donor plasmids were confirmed by PCR with a primer corresponding to the gentamicin resistance gene of the donor plasmid (P-gen-RV [5'-AGCCACCTACTCCCAACATC-3']) in combination with a primer corresponding to the bacmid sequence adjacent to the transposition site (M13/pUC forward primer [5'-CCCAGTCACGACGTTGTAAAACG-3']). Bacmid DNA, positive in the PCR, was electroporated into DH10ß cells to eliminate the helper plasmid and some residual untransposed bacmid DNA. Approximately 1 µg of DNA of each recombinant bacmid was transfected into 1.5 x 106 Sf21 or Sf9Op1D cells with 10 µl of Cellfectin (Invitrogen). At 5 days posttransfection, transfected cells were stained for GUS activity according to the Bac-to-Bac protocol (Invitrogen) to monitor transfection efficiency. The supernatant was clarified for 10 min at 2,200 x g and subsequently filter sterilized (0.45-µm pore size). One-fourth (500 µl) of the supernatant was used to infect 2.0 x 106 Sf9 or Sf9Op1D cells, respectively. At 72 h postinfection, cells were split into two portions. Cells of one portion were stained for GUS activity; the other portion was used at 10 days postinfection to monitor viral propagation. The gp64-positive bacmid served as a positive control for transfection and infection while the gp64-null bacmid was used as a negative control for transfection and infection (24). The SeFR149K bacmid was used as a negative control for F protein cleavage (24).
BV amplification and preparation. Viruses carrying f genes that rescued the gp64-null phenotype were amplified by infecting 1.0 x 107 Sf21 cells with 500 µl of cell supernatant from 10 days postinfection. Viruses carrying f genes that did not rescue the gp64 deletion in Sf21 cells were amplified in a similar manner by using Sf9Op1D cells. Cells were split every 3 to 5 days until all cells were infected. Amplified pseudotyped viruses were titrated on Sf9Op1D cells by a 50% tissue culture infective dose (TCID50) assay (30) and scored for infection by examining cells for GUS expression.
The genotypes of the pseudotyped viruses were confirmed by PCR on purified BV DNA by using primers P-SeF-mutant-FW (5'-GGCGTTGACGGTCGAGGCTAAAT-3') and P-SeF-mutant-RV (5'-GTGCATCGCTTTTTCGGTGAGAGG-3') to amplify a DNA fragment containing the incorporated restriction site (Table 1). The amplified DNA fragment was subsequently subjected to restriction enzyme analysis.
One-step growth experiments. To monitor infectious BV production from viruses carrying mutant f genes that rescued the gp64-null phenotype, viral growth results were generated by collecting infected cell supernatants. Sf21 cells (1.5 x 105 cells per well, 24-well plates) were infected at a multiplicity of infection (MOI) of 5.0 or 0.5 TCID50 U/cell for 1 h at 27°C. After infection, the inoculum was removed and 0.5 ml of fresh medium was added to the cells. At 0, 24, 48, 72, 69, and 144 h postinfection, the infected cell supernatants were collected. For each time point postinfection and each virus sample, duplicate samples were generated. The quantity of infectious BVs in the samples was determined by TCID50 assays on Sf9Op1D cells. A third sample was generated for those duplicated samples for which titers differed by a factor of 2.5 or more.
Western blot analysis. BVs were amplified by infecting 1.0 x 107 Sf21 or Sf9Op1D cells at an MOI of 0.5 TCID50 U/cell. Cells were split every 3 to 5 days until all cells were infected. BVs were purified from the supernatants as described previously (43). Equal amounts of BVs, determined by the Bradford method (5), were disrupted in Laemmli buffer (125 mM Tris-HCl, 2% sodium dodecyl sulfate, 5% 2-mercaptoethanol, 10% glycerol, 0.001% bromophenol blue [pH 6.8]) and denatured for 10 min at 95°C. Proteins were electrophoresed in sodium dodecyl sulfate-polyacrylamide gels and transferred onto Immobilon-P membranes (Millipore) by semidry electrophoresis transfer (3). Membranes were blocked overnight at 4°C in phosphate-buffered saline (PBS) containing 2% milk powder, followed by incubation for 1 h at room temperature with either polyclonal antibodies anti-F1 and anti-F2 (43), monoclonal antibody AcV5 (14), or polyclonal antibody anti-VP39 (40) (provided by A. L. Passarelli, Manhattan, Kans.), all at a 1:1,000 dilution in PBS containing 0.2% milk powder. After washing three times for 15 min in PBS containing 0.1% Tween-20, the membranes were incubated for 1 h at room temperature with a horseradish peroxidase-conjugated appropriate secondary antibody (Sigma, DAKO) in PBS containing 0.2% milk powder. After washing three times for 15 min in PBS containing 0.1% Tween-20, the signal was detected by enhanced chemiluminescence technology as described by the manufacturer (Amersham).
Computer-assisted analysis.
Protein comparisons with entries in the updated GenBank and EMBL were performed with the FASTA and BLAST programs (2, 34). Sequence alignments were performed with the program ClustalW (EMBL European Bioinformatics Institute, http://www.ebi.ac.uk) and edited with the Genedoc Software (28). The
-helix predictions were performed with the Protean software of DNASTAR by using the method of Garnier et al. (9).
|
|
|---|
F) (negative control), (ii) AcMNPV gp64 (positive control), (iii) SeMNPV f, (iv) SeMNPV fNdeI (f gene with silent mutation creating an NdeI cloning site), and (v) SeMNPV fK149R (f gene mutant negative in F0 cleavage). At 5 days posttransfection, cells were stained for GUS activity (Fig. 3A1 to O1). The presence of infectious BVs in the supernatant was determined by passaging the supernatants to new Sf21 cells. At 3 days postinfection, infected cells were demonstrated by their GUS activity (Fig. 3A2 to O2). The bacmids SeFL151R, SeFM155R, SeFG156A, SeFF152R, SeFV158R, SeFK160L, SeFF163R, SeFG164A, and SeFM166R were all able to produce infectious viruses (Fig. 3E to M), as were SeFNdeI (Fig. 3C) and the positive controls, AcGP64 and SeF (Fig. 3A and B). The bacmids SeFF152R and SeF
151-170 (Fig. 3F and N) and both negative controls (
F and SeFK149R) (Fig. 3D and O) were not able to produce infectious viruses, as expected. However, when those bacmids were transfected into Sf9Op1D cells, which constitutively express the Orgyia pseudogata MNPV GP64 protein to pseudotype AcMNPV (35), infectious BVs could be demonstrated (Fig. 3P to S), indicating that the defect in BV propagation was attributable to the expression of an inactive fusion protein.
![]() View larger version (148K): [in a new window] |
FIG. 3. Transfection-infection assays for viral propagation. Sf21 cells were transfected with indicated mutant gp64-null bacmids pseudotyped with f genes, incubated for 5 days, and stained for GUS activity (A1 to O1). Supernatants from the transfected cells were used to infect Sf21 cells (A2 to O2), which were incubated for 72 h and subsequently stained for GUS activity. Stained cells (infected cells) indicate that infectious virions were generated in the transfected cells. Bacmids that failed to propagate an infection in Sf21 cells (D2, F2, N2, and O2) were propagated in cells expressing constitutive O. pseudogata MNPV GP64 (Sf9Op1D). Sf9Op1D cells were transfected with indicated gp64-null bacmids (P1 to S1) and incubated for 5 days; then supernatants were transferred to Sf9Op1D and stained for GUS activity after 72 h (P2 to S2). Indicated gp64-null AcMNPV bacmids are pseudotyped with AcGP64 (AcMNPV gp64), SeF (SeMNPV f), SeFNdeI (SeMNPV f with silent mutation generating an NdeI restriction site), F (no envelope fusion gene), SeFL151R, SeFF152R, SeFM155R, SeFG156A, SeFV158R, SeFK160L, SeFF163R, SeFG164A, SeFM166R (SeMNPV f with mutations causing amino acid substitution in the putative fusion peptide as indicated in the subscript), SeF 151-170 (SeMNPV f with a deletion of the segment encoding amino acids 151 to 170), and SeFR149K (SeMNPV f with mutations causing an amino acid substitution in the furin cleavage site).
|
151-170 mutant showed a much smaller fragment (Fig. 4A). Along with the desired mutations, an additional restriction site was introduced into the f genes to mark the mutation (Table 1), allowing the analysis of the resulting PCR fragments by restriction enzyme analysis (Fig. 4B). From the patterns, it could be concluded that the gp64-null AcMNPV viruses contained the correct mutations.
![]() View larger version (46K): [in a new window] |
FIG. 4. PCR and restriction enzyme analyses of purified BV DNA to verify the genotype of indicated pseudotyped vAcGP64 viruses as described in the legend to Fig. 3. (A) PCR with f gene-specific primer pairs used to examine mutant viral DNAs amplifying an 834-bp fragment, when the virus contains the f gene, except for SeF 151-170, where a 773-bp fragment was amplified. (B) Restriction enzyme analysis of PCR-amplified DNA fragments. Mutant F genes have, in addition to the incorporated NdeI site, an additional restriction site, which is used to distinguish the viruses (Table 1). The SeFR149K mutant has neither a NdeI site nor an additional restriction site.
|
![]() View larger version (51K): [in a new window] |
FIG. 5. Western blot analysis of gp64-null BVs pseudotyped with indicated (mutant) f genes as described in the legend to Fig. 3. Infectious BVs were generated in Sf21 cells (lanes 1 to 3, 5, 6, and 8 to 13), and BVs, which are not able to propagate in Sf21 cells, were propagated in Sf9Op1D cells (lanes 4, 7, 14, and 15). Blots were probed with antibodies anti-F1 (A), anti-F2 (43) (B), and anti-GP64 (monoclonal antibody AcV5) (14) (C). (D) An anti-nucleocapsid antibody (anti-VP39) was used as an internal control for each preparation of purified BVs (40).
|
![]() View larger version (52K): [in a new window] |
FIG. 6. One-step growth results are shown for gp64-null AcMNPV viruses pseudotyped with wild-type SeF and SeF mutants as described in the legend to Fig. 3. Sf21 cells were infected with an MOI of 5.0 TCID50 U/cell (A) or 0.5 TCID50 U/cell (B), and supernatants were harvested at the indicated times postinfection and titrated on Sf9Op1D cells. Each data point represents the average of the results from two or three independent infections. Error bars represent standard deviations.
|
|
|
|---|
However, there are also some striking differences with vertebrate viral fusion peptides. Fusion peptides of the latter are rich in alanines while the first alanine (residue 22) in the SeMNPV F1 N terminus is found outside the conserved region. Another difference is that N-terminal fusion peptides of most vertebrate viral fusion proteins are generally apolar, whereas the SeMNPV F1 N terminus contains six polar amino acids (N153, H157, D159, K160, D167, and S168). Other baculovirus F proteins may have up to nine polar amino acids in this region (Fig. 1). However, the fusion peptide of influenza hemagglutinin also contains two to three polar residues (26). It is very well possible that the polar amino acids force the N terminus of F1 to insert in the membrane in a more perpendicular angle, with the polar amino acids to the hydrophilic side of the phospholipids compared to other fusion peptides.
The importance of the SeMNPV F1 N terminus for virus infection and propagation was investigated by a series of amino acid substitutions. AcMNPV virions, lacking gp64, were pseudotyped with mutant f genes and assayed (results are summarized in Table 2). A similar experimental system has been used to analyze the effect of mutations in the Ebola virus glycoprotein fusion peptide through pseudotyping of the vesicular stomatitis virus lacking its own fusion protein (18). The F protein with a deletion of the N terminus (SeF
151-170) was not able to produce infectious virus (Fig. 3), in spite of its ability to be incorporated in BVs and the occurrence of the posttranslational cleavage (Fig. 5). This suggests that this domain is not involved in virion assembly but plays an important role in baculovirus entry into cells.
|
View this table: [in a new window] |
TABLE 2. Summary of obtained resultsa
|
-helical conformation of the F1 N terminus. The G-to-A mutations in the Sendai virus fusion peptide led to increased fusion activity of the fusion protein (16) while for the Semliki Forest virus E1 protein it caused fusion at a lower pH (22). With the SeMNPV F protein, the G-to-A mutations showed no notable effect. However, these results are in line with results obtained for the Ebola virus glycoprotein fusion peptide (18), where one of the mutations of the glycines also had no effect on the virus titer and the incorporation of the fusion protein in virions. Arginine was substituted for conserved as well as nonconserved hydrophobic residues in the fusion peptide of the SeMNPV F protein. Introduction of a polar residue in the hydrophobic face of the amphipathic helix is expected to result in either a shorter (SeFL151R or SeFM166R), narrower (SeFF152R, SeFM155R, or SeFF163R), or disrupted (SeFV158R) hydrophobic face. The alterations can possibly disturb the helical conformation or the insertion of the helix in the host membrane and, hence, may have an effect on infectivity. Leucine was substituted for the conserved polar lysine (SeFK160L), which decreases the hydrogen bonding potency of the back face of the helix. Despite all the substitutions, there was no notable effect on incorporation of F proteins in BVs and on the processing of the mutant F proteins (Fig. 5). Only SeFF152R was not able to produce infectious virus (Fig. 3), suggesting a critical role of this amino acid in fusion. Similar results with an F-to-R conversion have been obtained for the Ebola glcyoprotein (18).
The virions pseudotyped with the SeFM155R, SeFF163R, SeFV158R (hydrophilic substitutions), and SeFK160L (hydrophobic substitution) genes were all impaired in their virus propagation dynamics (Fig. 6B). For SeFM155R, this could be caused by a reduced incorporation of F protein in BVs (Fig. 5, lane 7). In contrast, when cells were infected with a higher dose, only the titer of virus pseudotyped with SeFV158R was significantly lower than that of native SeF (Fig. 6A). Such a V-to-R conversion has been shown to reduce the fusion activity of the murine leukemia virus fusion protein (19). However, Western analysis suggested that the amount of BVs produced is extremely low (Fig. 5, lane 9). It is very well possible that this is due to a defect in transport of the protein to the cell membrane, caused by incorrect folding of the protein.
The mutations L151R and M166R did not result in a significant drop in virus titers, although the incorporation of SeFM166R in BVs was somewhat affected. The L151 and M166 residues are the first and the last hydrophobic amino acids of the putative fusion peptide, and this suggests that the F protein can properly function with a smaller hydrophobic face. However, this does not imply that the borders of the putative fusion peptide of SeMNPV F are well defined, because the two conserved aspartic acid residues D167 and D170 also appeared to be important for the fusogenic activity of the LdMNPV F protein (33).
The N-terminal domain of the SeMNPV F1 subunit is most likely involved in the entry and infectivity of BVs, and further credence is given for the role of this domain as a fusion peptide. Future biochemical studies involving the three-dimensional structure of the fusion peptide should indicate how the active fusion peptide is folded and how the behavior of the site-specific mutant fusion peptides can be explained. Experiments to this end are in progress.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»